Clinical Trial Update: Neoadjuvant Therapy With Ivonescimab Combined With Chemotherapy for Triple-Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial is evaluating Ivonescimab in combination with chemotherapy for triple-negative breast cancer, and the study is currently not recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Ivonescimab (AK112/SMT112)

Snippet

Sponsor: Fudan University | Conditions: TNBC, Triple Negative Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING